Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News23 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News22 hours agoHundreds pack neighbourhood for no-reserve auction of ready-made charity home
-
General11 hours agoTexas opens probe into Kellogg’s health claims, dyes